Summary
This article discusses data from RHAPSODY [NCT00478660; AS], ReAct [NCT00650026; RA], and STEREO [NCT00235885; PsA] - 3 open-label trials that examined the effectiveness of adalimumab treatment in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriatic arthritis who had a history of anti-TNF therapy.
- inflammatory disorders clinical trials
- rheumatoid arthritis
- arthritis
- © 2008 MD Conference Express
Tools
Adalimumab Therapy is Effective and Well Tolerated in AS, RA, and PsA Patients with a History of Insufficient Response or Intolerance to Other Anti—TNF Therapies
Permalink:
Table of contents
Cited By...
- No citing articles found.